• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Evolus Inc.

    6/16/25 4:03:36 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EOLS alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001700836
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    EVOLUS, INC.
    SEC File Number
    001-38381
    Address of Issuer
    520 Newport Center Drive, Suite 1200
    Newport Beach
    CALIFORNIA
    92660
    Phone
    (949) 284-4555
    Name of Person for Whose Account the Securities are To Be Sold
    DAVID MOATAZEDI
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer
    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    16582164052.366447558906/16/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common05/09/2025Performance SharesIssuerCheckbox not checked1481405/09/2025Not Applicable
    Common03/26/2025Restricted StockIssuerCheckbox not checked176803/26/2025Not Applicable

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    DAVID MOATAZEDI
    520 Newport Center Drive, Suite 1200
    Newport Beach � CA � 92660
    Common06/13/2025419542172.75
    DAVID MOATAZEDI
    520 Newport Center Drive, Suite 1200
    Newport Beach � CA � 92660
    Common06/13/202516135162206.77
    DAVID MOATAZEDI
    520 Newport Center Drive, Suite 1200
    Newport Beach � CA � 92660
    Common06/13/2025989999515.64
    DAVID MOATAZEDI
    520 Newport Center Drive, Suite 1200
    Newport Beach � CA � 92660
    Common06/13/202525617257530.26
    DAVID MOATAZEDI
    520 Newport Center Drive, Suite 1200
    Newport Beach � CA � 92660
    Common06/13/202522465225842.89
    DAVID MOATAZEDI
    520 Newport Center Drive, Suite 1200
    Newport Beach � CA � 92660
    Common06/13/202533012331872.94
    DAVID MOATAZEDI
    520 Newport Center Drive, Suite 1200
    Newport Beach � CA � 92660
    Common05/12/202515787155754.54
    DAVID MOATAZEDI
    520 Newport Center Drive, Suite 1200
    Newport Beach � CA � 92660
    Common03/27/2025625177512.40
    DAVID MOATAZEDI
    520 Newport Center Drive, Suite 1200
    Newport Beach � CA � 92660
    Common03/18/20251037361375020.68

    144: Remarks and Signature

    Remarks
    Date of Notice
    06/16/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ David Moatazedi

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $EOLS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $EOLS

    DatePrice TargetRatingAnalyst
    4/17/2025$21.00Buy
    BTIG Research
    1/29/2024$10.00 → $16.00Equal Weight → Overweight
    Barclays
    6/23/2022$18.00Buy
    Needham
    5/12/2022$8.00 → $10.00Underweight → Equal Weight
    Barclays
    1/20/2022$11.00Hold → Buy
    Truist
    11/3/2021$22.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EOLS
    SEC Filings

    See more
    • SEC Form 144 filed by Evolus Inc.

      144 - Evolus, Inc. (0001570562) (Subject)

      6/16/25 4:03:36 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - Evolus, Inc. (0001570562) (Filer)

      6/6/25 4:20:52 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Evolus, Inc. (0001570562) (Filer)

      5/27/25 4:18:36 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director White Albert G Iii bought $189,000 worth of shares (20,000 units at $9.45), increasing direct ownership by 66% to 50,378 units (SEC Form 4)

      4 - Evolus, Inc. (0001570562) (Issuer)

      6/10/25 5:04:47 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in July of an aggregate of 12,385 restricted stock units (RSUs) of the company's common stock to 6 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant date and vesting commencement date of July 7, 2025, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest 25% on each annual anniversary of the ves

      7/11/25 4:05:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France

      Launching into this key growth market1 as part of the company's geographic expansion strategy Evolus to provide Nuceiva® to French medical aesthetics healthcare professionals through its partnership with Symatese enabling direct order and delivery Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has partnered with Symatese to commence distribution of Nuceiva® (botulinum toxin type A) in France. Nuceiva® is approved by the European Commission for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), wh

      7/9/25 8:00:00 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in June of non-qualified stock options to purchase an aggregate of 11,628 shares of Evolus and an aggregate of 36,077 restricted stock units (RSUs) of the company's common stock to 17 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus 2023 Inducement Incentive Plan, with a grant date of June 8, 2025 and vesting commencement date of June 7, 2025, as an inducement material to the new employees entering into employment with Evolus in accor

      6/13/25 4:05:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Evolus with a new price target

      BTIG Research initiated coverage of Evolus with a rating of Buy and set a new price target of $21.00

      4/17/25 8:32:06 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus upgraded by Barclays with a new price target

      Barclays upgraded Evolus from Equal Weight to Overweight and set a new price target of $16.00 from $10.00 previously

      1/29/24 7:09:38 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham initiated coverage on Evolus with a new price target

      Needham initiated coverage of Evolus with a rating of Buy and set a new price target of $18.00

      6/23/22 7:38:38 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Moatazedi David sold $1,283,195 worth of shares (127,905 units at $10.03), decreasing direct ownership by 26% to 364,927 units (SEC Form 4)

      4 - Evolus, Inc. (0001570562) (Issuer)

      6/16/25 4:42:06 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director White Albert G Iii bought $189,000 worth of shares (20,000 units at $9.45), increasing direct ownership by 66% to 50,378 units (SEC Form 4)

      4 - Evolus, Inc. (0001570562) (Issuer)

      6/10/25 5:04:47 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Avelar Rui sold $33,397 worth of shares (3,385 units at $9.87), decreasing direct ownership by 0.93% to 359,082 units (SEC Form 4)

      4 - Evolus, Inc. (0001570562) (Issuer)

      5/14/25 7:27:50 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    Leadership Updates

    Live Leadership Updates

    See more
    • Evolus Announces Appointment of Albert G. White III to Board of Directors

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes

      7/1/24 8:00:00 AM ET
      $COO
      $EOLS
      Ophthalmic Goods
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Nareg Sagherian has joined the Company as Vice President, Head of Global Investor Relations and Corporate Communications. In this role, Nareg will be responsible for interacting with current and prospective investors and managing a strategic investor relations and corporate communications program. Nareg will report to Sandra Beaver, Chief Financial Officer of Evolus. "I am thrilled to welcome Nareg to our team," said Sandra Beaver, Chief Financial Officer of Evolus. "Nareg's unique experience will enable him to drive a successful investor relati

      1/4/24 4:05:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer

      Industry Leader Brings 20+ Years of Cosmetic Expertise to the Performance Beauty Category Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, has named Ms. Tomoko Yamagishi-Dressler as Chief Marketing Officer (CMO), effective today. Yamagishi-Dressler is an accomplished executive with more than two decades of established excellence leading omnichannel marketing for global beauty companies. A true strategist, Yamagishi-Dressler has successfully driven profitable business growth and increased equity for an iconic portfolio of industry brands. This press release features multimedia. View the full release here: https:

      8/21/23 8:45:00 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Evolus Inc.

      SC 13G/A - Evolus, Inc. (0001570562) (Subject)

      11/14/24 4:50:28 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Evolus Inc.

      SC 13G/A - Evolus, Inc. (0001570562) (Subject)

      11/14/24 4:00:06 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Evolus Inc.

      SC 13G/A - Evolus, Inc. (0001570562) (Subject)

      11/13/24 5:38:05 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    Financials

    Live finance-specific insights

    See more
    • Evolus Reports First Quarter 2025 Results

      Global Net Revenue of $68.5 Million for Q1 2025, Up 15.5% from Q1 2024 Meaningfully Outperformed Toxin Market Share Guidance Assumptions in Slower Market GAAP Operating Loss of $15.2 Million and Non-GAAP Operating Loss of $5.5 Million for the First Quarter; Remains On Track to Achieving Positive Non-GAAP Operating Income on a Consolidated Basis for the Full-Year 2025 Evolysse™ Launched in Q2 and Off to a Strong Start Reaffirms 2025 Net Revenue Guidance of $345 Million to $355 Million; Evolysse™ and Estyme® Injectable Hyaluronic Acid (HA) Gels Anticipated to Contribute 8 to 10% of Total Revenue for the Full-Year 2025 Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a

      5/7/25 4:05:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus to Report First Quarter Financial Results on May 7, 2025

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (800) 579-2543 (U.S.) or (785) 424-1789 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephonic replay

      4/23/25 8:00:00 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

      Global Net Revenue Record of $79.0 Million for the Fourth Quarter and $266.3 Million for the Full-Year 2024, Representing 30% and 32% Growth Over the Prior Year, Respectively; Results Unchanged from January Preliminary Results GAAP Operating Loss Improved to $2.3 Million for the Fourth Quarter and $34.4 Million for the Full-Year 2024; Second Quarter of Profitability1 with Positive Non-GAAP Operating Income of $6.7 Million for Q4 2024 and Achieved Full-Year Profitability1 One Year Ahead of Expectations with Positive Non-GAAP Operating Income of $0.3 Million for FY 2024; On Track to Expanding Non-GAAP Operating Income Margins and Cash Generation Full-Year 2024 Non-GAAP Operating Expense

      3/4/25 4:05:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care